At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,712 enrolled
Drug / intervention
fesoterodine fumarate +2 moredrug
Likely dose
fesoterodine fumarate 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)
In Brief
A Phase 3 clinical trial evaluating fesoterodine fumarate, placebo, and 1 other intervention for Overactive Bladder. Completed, enrolled 1,712 participants across 178 sites in 29 countries.
Detailed Summary
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesBelgium, Brazil, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, Germany, Greece, Hong Kong, Hungary, India, Italy, Malaysia, Norway, Peru, Poland, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartApr 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedMar 8, 2007
Enrollment StartApr 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.3 years ago
Interventions
fesoterodine fumaratedrug
4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
placebodrug
once daily (OD)for 12 weeks
tolterodine tartratedrug
4 mg once daily (OD) for 12 weeks